| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Metanephrine is an inactive metabolite and does not have a therapeutic target. It is a product of the O-methylation of epinephrine by catechol O-methyltransferase. As a biomarker, it is used for the diagnosis of pheochromocytoma. Elevated levels of metanephrine in plasma or urine indicate the presence of this catecholamine-secreting tumor.
|
|---|---|
| ln Vitro |
Rat hepatocytes and Caki-1 cells cannot absorb MPP+; the IC50 values for these two cell types are 302.0 µM and 34.2 µM, respectively[2].
In vitro, Metanephrine inhibits MPP+ uptake into Caki-1 cells and rat hepatocytes with IC50s of 34.2 µM and 302.0 µM, respectively. This activity is related to its role as a catecholamine metabolite. The compound is used in research for the diagnosis of pheochromocytoma. |
| ln Vivo |
In vivo, Metanephrine is used as a diagnostic marker for pheochromocytoma. Elevated levels of free metanephrine in blood plasma or urine samples are used to identify patients with this condition. The compound is not used as a therapeutic agent.
|
| Enzyme Assay |
The in vitro assay for Metanephrine involves measuring its inhibition of MPP+ uptake. Caki-1 cells or rat hepatocytes are incubated with MPP+ in the presence of varying concentrations of Metanephrine. The IC50 values are determined by quantifying the reduction in MPP+ uptake.
|
| Cell Assay |
Cellular assays for Metanephrine are performed using Caki-1 cells or rat hepatocytes. Cells are treated with Metanephrine at various concentrations, and the uptake of MPP+ is measured. The compound's ability to inhibit MPP+ uptake is assessed.
|
| Animal Protocol |
In vivo animal studies for Metanephrine are not applicable, as it is used as a diagnostic biomarker rather than a therapeutic agent. Its levels are measured in patient samples for the diagnosis of pheochromocytoma.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Metanephrine are not applicable in a therapeutic context. It is a metabolite that is measured in plasma and urine for diagnostic purposes. The compound has a molecular weight of 197.23 g/mol.
|
| Toxicity/Toxicokinetics |
Toxicity data for Metanephrine are not reported in the available sources. As an endogenous metabolite, it is not considered toxic. It is used as a diagnostic marker.
|
| References |
|
| Additional Infomation |
Metanephrine is a catecholamine. It is a product of the O-methylation of epinephrine by catechol O-methyltransferase and has no physiological activity itself. Elevated levels of free Metanephrine in patient plasma samples may be one of the diagnostic indicators of pheochromocytoma. It is a product of epinephrine O-methylation and a common, pharmacologically and physiologically inactive epinephrine metabolite.
Metanephrine is an O-methylated metabolite of epinephrine used as a diagnostic marker for pheochromocytoma. Elevated levels in blood or urine indicate the presence of this tumor. The compound is available from chemical suppliers for research and diagnostic purposes. |
| Molecular Formula |
C10H15NO3
|
|---|---|
| Molecular Weight |
197.231
|
| Exact Mass |
197.105
|
| CAS # |
5001-33-2
|
| Related CAS # |
881-95-8 (HCl);5001-33-2;
|
| PubChem CID |
21100
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
378.8±42.0 °C at 760 mmHg
|
| Melting Point |
180-182ºC
|
| Flash Point |
182.9±27.9 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.557
|
| LogP |
-0.32
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
14
|
| Complexity |
165
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
JWJCTZKFYGDABJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H15NO3/c1-11-6-9(13)7-3-4-8(12)10(5-7)14-2/h3-5,9,11-13H,6H2,1-2H3
|
| Chemical Name |
4-[1-hydroxy-2-(methylamino)ethyl]-2-methoxyphenol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~633.78 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.0702 mL | 25.3511 mL | 50.7022 mL | |
| 5 mM | 1.0140 mL | 5.0702 mL | 10.1404 mL | |
| 10 mM | 0.5070 mL | 2.5351 mL | 5.0702 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
